NYTimes: Government Needs to Aid Industry Research

Brad Spellberg is a professor of medicine at the Los Angeles Biomedical Research Institute at Harbor-U.C.L.A. Medical Center. He is the co-author of “Rising Plague: The Deadly Threat from Deadly Bacteria and Our Dwindling Arsenal  to Fight Them.”

New LA BioMed team takes on glaucoma in African-Americans

Sandy Mazza, Daily Breeze

 

Continuous, Combined Hormone Replacement Therapy Protects Against Endometrial Cancer

The ASCO Post

By Caroline Helwick
December 15, 2013, Volume 4, Issue 20

According to an analysis of the Women’s Health Initiative, continuous combined use of estrogen plus progestin reduces the risk of endometrial cancer among postmenopausal women. The study was reported at the 2013 European Cancer Congress byRowan T. Chlebowski, MD, PhD, Professor and Chief of Medical Oncology/Hematology at the David Geffen School of Medicine at UCLA and Harbor-UCLA Medical Center, Los Angeles.1

Important Findings

International study finds lower-dose IUDs are safe and effective Findings suggest expanded use of these contraceptive devices

LOS ANGELES – (Dec. 5, 2013) – In a finding that could expand the use of one of the most effective forms of birth control, two intrauterine contraceptive systems that had lower doses of the contraceptive hormone, levonorgestrel, were found to be safe and effective in preventing pregnancies, according to an international study that included researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed).